VIDEO: Recent developments in breast cancer prevention

Editor’s note: This is an automatically generated transcript. Please notify editor@healio.com if there are concerns regarding accuracy of the transcription.

I think we've been really fortunate over the last couple of years to see the largest number of FDA approvals that we've had in breast cancer. At least the pace of approvals has dramatically changed. And so I think there are lots of new targeted agents that we're seeing improve outcomes for our breast cancer patients. Some examples include agents like antibody drug conjugates. So these are in essence, antibodies that are able to target a particular receptor that's present on a breast cancer cell and then deliver chemotherapy into the cancer cell. And so we can get a lot more chemo into the cell than we can give with traditional chemotherapy. And we're seeing that this is dramatically improving outcomes when compared to traditional chemotherapy. We also have several new targeted agents that have been approved that are oral agents. Some examples include things like capivasertib, which is an oral agent that targets a PI3K AKT pathway. We also have an oral SERD, so a selective estrogen receptor degrader that can kind of chew up the estrogen receptor. And that agent that's been approved so far is Elacestrant. And so we're seeing a lot of these new, again, targeted agents come about, but they're specific for patients whose tumors harbor particular mutations. And I think this movement really highlights the fact that many of our new drugs are being developed in a more personalized manner that we have to know if a target's present on that patient's tumor, or we have to know if that tumor harbors a particular alteration to really understand what the optimal therapy is for that patient.